Tfh cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon-α therapy. [electronic resource]
Producer: 20170907Description: 37-45 p. digitalISSN:- 1872-9142
- Adult
- Antiviral Agents -- therapeutic use
- Female
- Flow Cytometry
- Hepatitis B Surface Antigens -- blood
- Hepatitis B e Antigens -- blood
- Hepatitis B, Chronic -- drug therapy
- Humans
- Immunity, Humoral -- immunology
- Interferon-alpha -- therapeutic use
- Longitudinal Studies
- Male
- Seroconversion -- drug effects
- T-Lymphocytes, Helper-Inducer -- immunology
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.